Online inquiry

IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9152MR)

This product GTTS-WQ9152MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9152MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9137MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ14865MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ11552MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ10751MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ7885MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ12881MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ13689MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW